Skip to content
Screener

Celldex Therapeutics CLDX Business Segments — Other Research And Development Expense

Similar metrics at other companies

Alumis Inc. logo
ALMSSingle Reportable — Other Research And Development Expense
$2.37M+3.2%
Dogwood Therapeutics logo
DWTXSingle Reportable — Other Research And Development Expense
$585.61K+33.4%
UroGen Pharma logo
URGNSingle Reportable — Other Research And Development Expense
$258K+119%
Lantheus Holdings logo
LNTHReportable — Other Research And Development Expense
$29.73M-18.7%
Solid Biosciences Inc. logo
SLDBExternal Research And Development Other — Other Research And Development Expense
$1.98M-36.4%
TG Therapeutics logo
TGTXOther Research And Development Expense
$87.27M+218%

Other financials

Income statement

See full
Revenue$22.0K-97.0%
Operating income-$80.6M-26.3%
Net income-$73.5M-29.9%
EPS (diluted)-$0.94-10.6%

Balance sheet

See full
Cash & equivalents$47.5M+106%
Total debt$4.9M+61.8%
Total equity$714.6M+9.0%
Total assets$782.3M+13.0%

Cash flow

See full
Operating cash flow-$57.4M-30.5%
CapEx$3.2M+337%
Free cash flow-$60.6M-35.4%

Valuation

See full
Market cap$3.26B+129%
Enterprise value$3.22B+129%
P/S20,646.4×+20,401×

Profitability

See full
Operating margin-206,220.3%-210,440pp
Net margin-190,220.9%-193,797pp
FCF margin-153,231%-156,630pp

Returns & leverage

See full
Return on equity-43.9%+70.0pp
Debt / equity0.0×
Current ratio11.8×-7.8×

Where this comes from

Reported directly by Celldex Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.

The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-091984
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Personnel$15,885$14,129$31,454$27,729
Laboratory supplies2,5931,5444,0513,712
Facility1,1781,3982,1182,803
Product development (b)41,74633,53691,90365,702
Other expenses (c)6,1403,58911,0176,864
Total R&D expense$67,542$54,196$140,543$106,810

Item 1. Unaudited Financial Statements

FAQ

What is Celldex Therapeutics's business segments — other research and development expense?
Celldex Therapeutics (CLDX) reported business segments — other research and development expense of $6.14M in Q2 2026.
How has Celldex Therapeutics's business segments — other research and development expense changed year-over-year?
Celldex Therapeutics's business segments — other research and development expense increased by 71.1% year-over-year, from $3.59M to $6.14M.
What is the long-term trend for Celldex Therapeutics's business segments — other research and development expense?
Over 3 years (2022 to 2025), Celldex Therapeutics's business segments — other research and development expense has grown at a 34.5% compound annual growth rate (CAGR), from $6.35M to $15.48M.
What does business segments — other research and development expense mean?
This metric captures miscellaneous research and development costs within the primary business segment that do not fall into major categories like personnel or direct product development. It may include consulting fees, regulatory filing costs, or specialized outsourced research services. Monitoring this helps identify secondary drivers of the company's overall research expenditure.

Ask your AI about Celldex Therapeutics's business segments — other research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude